Skip to main content
Ocugen, Inc. logo

Ocugen, Inc. — Investor Relations & Filings

Ticker · OCGN ISIN · US43358V1098 LEI · 549300JVNUI9CXWJLR09 US Manufacturing
Open in API
Filings indexed 849 across all filing types
Latest filing 2016-10-27 Regulatory Filings
Country US United States of America
Listing US OCGN

About Ocugen, Inc.

https://ocugen.com/

Ocugen, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and commercializing novel gene therapies, cell therapies, and vaccines. The company's primary mission is to develop treatments for blindness diseases, leveraging its first-in-class modifier gene therapy platform. This platform represents a potential paradigm shift in treating inherited retinal diseases by aiming to address multiple genetic mutations with a single product. In addition to its focus on ocular health, Ocugen is also advancing a pipeline that includes vaccines for infectious diseases. The company is dedicated to addressing significant unmet medical needs and providing innovative therapeutic options for patients with debilitating conditions.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2016
Regulatory Filings Classification · 95% confidence The document is a letter from a law firm to the SEC commenting on a Preliminary Proxy Statement on Schedule 14A filed by Histogenics Corporation. It discusses revisions to the proxy statement, including disclosures about investors and beneficial ownership tables. The document references the proxy statement and responses to SEC comments but does not contain the proxy statement itself or detailed shareholder solicitation materials. The document length is short (2656 characters) and is primarily correspondence regarding the proxy statement. According to the classification rules, such correspondence related to proxy statements is best classified as Regulatory Filings (RNS) because it is a regulatory communication and not the proxy statement itself or a voting results announcement.
2016-10-27 English
PRER14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A filing, which is a proxy statement filed pursuant to Section 14(a) of the Securities Exchange Act of 1934. It includes detailed information about a special meeting of stockholders, voting procedures, proposals to be voted on, and recommendations from the board of directors. The content focuses on soliciting shareholder votes for a specific proposal related to stock issuance and includes proxy voting instructions. This matches the definition of Proxy Solicitation & Information Statement (PSI), which are materials sent to shareholders to provide information and request votes for meetings. The document is not an announcement of a report, nor is it a full annual or interim report, earnings release, or other financial filing. Therefore, the correct classification is PSI with high confidence.
2016-10-27 English
Regulatory Filings 2016
Regulatory Filings
2016-10-25 English
8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content specifically mentions a press release about enrollment progress in a Phase 3 clinical trial. The document is short (2981 characters) and primarily serves to disclose this event and attach the press release as an exhibit. There are no financial statements or detailed financial data presented. The document is not an annual or quarterly report, nor is it an earnings release or management discussion. It is a regulatory filing used to disclose material events promptly. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2016-10-24 English
Regulatory Filings 2016
Regulatory Filings
2016-10-12 English
SC 13D/A
Major Shareholding Notification
2016-10-06 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.